Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial
Researchers at the Ohio State University have successfully tested a new trispecific CAR T-cell therapy for B-cell blood cancers in a Phase I clinical trial. The treatment uses the OX40 protein to boost immune response and features a faster cell preparation process.
Why it matters
This advancement offers a potential breakthrough for patients with treatment-resistant blood cancers, demonstrating improved efficacy and a more efficient clinical workflow.
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Immunophenotypic and functional characteristics of CD8 + CAR + T cells and CD4 + CAR + T cells in trispecific CAR T infusion products. Patient’s trispecific CAR T infusion products were analyzed via spectral flow cytometry. Credit: Blood Cancer Discovery (2026). DOI: 10.1158/2643-3230.bcd-26-0186 Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers. The findings are published in Blood Cancer Discovery .
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in